• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Kintz Samuel

    2/15/24 8:56:11 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kintz Samuel

    (Last) (First) (Middle)
    C/O ENLIVEN THERAPEUTICS, INC.
    6200 LOOKOUT ROAD

    (Street)
    BOULDER CO 80301

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Enliven Therapeutics, Inc. [ ELVN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    PRESIDENT AND CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    02/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $14.85 02/13/2024 A 410,000 (1) 02/12/2034 Common Stock 410,000 $0 410,000 D
    Explanation of Responses:
    1. 1/4th of the shares subject to the option will vest on February 13, 2025 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
    /s/ Ben Hohl, by power of attorney 02/15/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Imara Announces Stockholder Approval of Merger With Enliven

      -- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into

      2/22/23 4:01:00 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lifshitz Law PLLC Announces Investigations of IMRA, AGFS, USER, and PEBO

      NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a

      11/23/22 7:48:00 PM ET
      $AGFS
      $IMRA
      $PEBO
      $USER
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Banks
      Finance
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care